Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6634
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mirko Peitzsch | - |
dc.contributor.author | Novos T | - |
dc.contributor.author | Kaden D | - |
dc.contributor.author | Kurlbaum M | - |
dc.contributor.author | Antonius Eduard van Herwaarden | - |
dc.contributor.author | Müller D | - |
dc.contributor.author | Adaway J | - |
dc.contributor.author | Grouzmann E | - |
dc.contributor.author | McWhinney B | - |
dc.contributor.author | Hoad K | - |
dc.contributor.author | Gerald Woollard | - |
dc.contributor.author | Kema I | - |
dc.contributor.author | Boot C | - |
dc.contributor.author | Fassnacht M | - |
dc.contributor.author | Sweep F | - |
dc.contributor.author | Tze Ping Loh | - |
dc.contributor.author | Horvath AR | - |
dc.contributor.author | Eisenhofer G | - |
dc.date.accessioned | 2025-03-29T23:23:56Z | - |
dc.date.available | 2025-03-29T23:23:56Z | - |
dc.date.issued | 2021 | - |
dc.identifier.uri | https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6634 | - |
dc.description.abstract | <h4>Background</h4>Plasma-free normetanephrine and metanephrine (metanephrines) are the recommended biomarkers for testing of pheochromocytoma and paraganglioma (PPGL). This study evaluated the status of harmonization of liquid chromatography-tandem mass spectrometry-based measurements of plasma metanephrines and methoxytyramine and clinical interpretation of test results.<h4>Methods</h4>125 plasma samples from patients tested for PPGLs were analyzed in 12 laboratories. Analytical performance was also assessed from results of a proficiency-testing program. Agreement of test results from different laboratories was assessed by Passing-Bablok regression and Bland-Altman analysis. Agreement in clinical test interpretation based on laboratory specific reference intervals was also examined.<h4>Results</h4>Comparisons of analytical test results by regression analysis revealed strong correlations for normetanephrine and metanephrine (R ≥ 0.95) with mean slopes of 1.013 (range 0.975-1.078), and 1.019 (range 0.963-1.081), and intercepts of -0.584 (-53.736 to 54.790) and -3.194 (-17.152 to 5.933), respectively. The mean bias between methods was 1.2% (-11.6% to 16.0%) for metanephrine and 0.1% (-18.0% to 9.5%) for normetanephrine. Measurements of 3-methoxytyramine revealed suboptimal agreement between laboratories with biases ranging from -32.2% to 64.0%. Interrater agreement in test interpretation was >94% for metanephrine and >84% for normetanephrine; improvements in interrater agreement were observed with use of harmonized reference intervals, including age-specific cut-offs for normetanephrine.<h4>Conclusions</h4>Analytical methods for metanephrines are well harmonized between laboratories. However, the 16% disagreement in test interpretation for normetanephrine suggests use of suboptimal method-dependent reference intervals for clinical decision-making for this metabolite. Improved analytical methods and reference interval harmonization are particularly required for 3-methoxytyramine. | - |
dc.relation.ispartof | Clinical chemistry | - |
dc.title | Harmonization of LC-MS/MS Measurements of Plasma Free Normetanephrine, Metanephrine, and 3-Methoxytyramine. | - |
dc.type | Journal Article | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
Appears in Sites: | Queensland Health Publications |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.